克隆號(hào)2.43單克隆抗體能與小鼠CD8α反應(yīng)。CD8抗原是一種跨膜糖蛋白，作為T(mén)細(xì)胞受體的共受體。與TCR一樣，CD8與抗原呈遞細(xì)胞(APC)展示的class I MHC分子結(jié)合。CD8主要在細(xì)胞毒性T細(xì)胞表面表達(dá)，也可在胸腺細(xì)胞、NK細(xì)胞和一些樹(shù)突狀細(xì)胞亞群上表達(dá)。CD8最常見(jiàn)的存在形式是由一個(gè)CD8α和一個(gè)CD8β鏈組成的異二聚體，然而，它也可以是由兩個(gè)CD8α鏈組成的同二聚體。CD8α和CD8β鏈均與免疫球蛋白可變輕鏈具有顯著同源性。每個(gè)CD8鏈的分子量約為34 kDa。當(dāng)在體內(nèi)使用時(shí)，克隆號(hào)2.43抗體表現(xiàn)出depleting活性。
產(chǎn)品詳情
產(chǎn)品貨號(hào)
BE0061
產(chǎn)品規(guī)格
1/5/25/50/100mg
抗體亞型
Rat IgG2b, κ
推薦同型對(duì)照
InVivoMAb rat IgG2b isotype control, anti-keyhole limpet hemocyanin（貨號(hào)：BE0090）
Balogh, K. N., et al. (2018). “Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses." PLoS One 13(6): e0197702.
in vivo CD8+ T cell depletion
Li, J., et al. (2018). “Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8(+) T Cells." Immunity 48(4): 773-786 e775.
in vivo CD8+ T cell depletion
Moynihan, K. D., et al. (2016). “Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses." Nat Med. doi: 10.1038/nm.4200.
在線(xiàn)咨詢(xún)
電話(huà)咨詢(xún)
